RBL Communications
  • Home
  • About
  • Services
  • Investment Hub
  • Contact
Select Page

Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.

Feb 12, 2020

TORONTO, Feb. 12, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) is pleased to announce that it has entered into a letter of intent, dated February 11, 2020 (the “LOI”) with Psilocin Pharma Corp. (“Psilocin”), an arm’s length party incorporated...

Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

Jan 20, 2020

TORONTO, Jan. 20, 2020 – Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update, further to the Company’s...

Revive Therapeutics Provides Update on its Clinical Development Plan For Rare Liver Diseases

Jan 6, 2020

TORONTO, Jan. 06, 2020 – Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update on the Company’s clinical...
Next Entries »

Follow Us

Categories

  • Al O'Grady
  • Anfield Energy
  • Blog
  • Boba Mint Holdings
  • Kontrol Energy
  • News
  • PharmaDrug
  • Revive
  • Uncategorized
  • Home
  • About
  • Services
  • Investment Hub
  • Contact
  • Facebook
  • X
© COPYRIGHT 2025. RBL Communications Inc. ALL RIGHTS RESERVED.